Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADI-PEG20 in adolescents with obesity and prediabetes
NCT05829239Phase 2Withdrawn
- Sponsor
- Washington University School of Medicine
- Start
- Apr 2024
- Primary completion
- Apr 2024
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of Pegargiminase in prediabetes, obesity, sponsored by Washington University School of Medicine. Planned start Apr 2024; status: withdrawn.
02
Drugs
Pegargiminase
03
Conditions
prediabetesobesity
Beyond the preview
Go deeper on NCT05829239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05829239.